Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jun 15;124(12):2541-2551.
doi: 10.1002/cncr.31374. Epub 2018 Apr 12.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Sonali M Smith  1 , James Godfrey  2 , Kwang Woo Ahn  3   4 , Alyssa DiGilio  3 , Sairah Ahmed  5 , Vaibhav Agrawal  6 , Veronika Bachanova  7 , Ulrike Bacher  8   9 , Asad Bashey  10 , Javier Bolaños-Meade  11 , Mitchell Cairo  12 , Andy Chen  13 , Saurabh Chhabra  14 , Edward Copelan  15 , Parastoo B Dahi  16 , Mahmoud Aljurf  17 , Umar Farooq  18 , Siddhartha Ganguly  19 , Mark Hertzberg  20 , Leona Holmberg  21 , David Inwards  22 , Abraham S Kanate  23 , Reem Karmali  24 , Vaishalee P Kenkre  25 , Mohamed A Kharfan-Dabaja  26 , Andreas Klein  27 , Hillard M Lazarus  28 , Matthew Mei  29 , Alberto Mussetti  30 , Taiga Nishihori  26 , Praveen Ramakrishnan Geethakumari  31 , Ayman Saad  32 , Bipin N Savani  33 , Harry C Schouten  34 , Nirav Shah  14 , Alvaro Urbano-Ispizua  35   36   37 , Ravi Vij  38 , Julie Vose  39 , Anna Sureda  40 , Mehdi Hamadani  3
Affiliations
Comparative Study

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

Sonali M Smith et al. Cancer. .

Abstract

Background: Early treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high-risk group of patients with an expected 5-year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.

Methods: This study compared autologous hematopoietic stem cell transplantation (auto-HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo-HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto-HCT or allo-HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression-free survival, relapse, and nonrelapse mortality (NRM).

Results: Four hundred forty FL patients had ETF (auto-HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow-up of 69 to 73 months, the adjusted probability of 5-year OS was significantly higher after auto-HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P = .0008). The 5-year adjusted probability of NRM was significantly lower for auto-HCT (5%) versus MSD (17%) or MUD HCT (33%; P < .0001). The 5-year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto-HCT (58%; P < .0001).

Conclusions: Patients with high-risk FL, as defined by ETF, undergoing auto-HCT for FL have low NRM and a promising 5-year OS rate (70%). MSD HCT has lower relapse rates than auto-HCT but similar OS. Cancer 2018;124:2541-51. © 2018 American Cancer Society.

Keywords: allogeneic transplantation; autologous transplantation; chemoimmunotherapy; early treatment failure; follicular lymphoma; rituximab.

PubMed Disclaimer

Conflict of interest statement

Disclosure of conflict of interest: No disclosures to report.

Figures

Figure 1
Figure 1
(a) Adjusted probabilities of non-relapse mortality (NRM), (b) relapse, (c) progression-free survival (PFS), and (d) overall survival (OS) for patients who underwent autologous (auto) hematopoietic cell transplantation versus matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic transplant.
See this image and copyright information in PMC

Comment in

References

    1. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122:981–987. - PMC - PubMed
    1. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23:5019–5026. - PubMed
    1. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452. - PubMed
    1. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015;33:2516–2522. - PMC - PubMed
    1. Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91:1096–1101. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources